Diabetes mellitus, sometimes known as diabetes, is a chronic disease in which blood glucose levels are higher than usual. Semaglutide is a diabetic medicine used to treat type 2 diabetes. The medication functions similarly to a natural hormone, glucagon-like peptide-1, in that it promotes insulin release in the body to regulate blood glucose levels. The treatment, coupled with diet and exercise, is advised by the US Food and Drug Administration (FDA) to manage blood sugar levels in type 2 diabetes patients.Over the projected period, the rising incidence of type 2 diabetes is likely to drive growth in the worldwide semaglutide market. For example, according to a Centres for Disease Control and Prevention (CDC) report, around 23.1 million people Diabetes was diagnosed, 132,000 of them were children and adolescents. The research also said that type 2 diabetes accounted for 90% to 95% of all diabetes occurrences. Furthermore, prominent companies' activities, campaigns, and programmes to prevent and control diabetes are likely to boost market expansion throughout the forecast period.North America held the greatest market share in 2018, thanks to the region's new semaglutide product launches and approvals.
Key Companies in the Semaglutide Industry:
Novo Nordisk
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The company collaboration agreements with Gilead Sciences, Inc. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. in September 2019, Novo Nordisk received the approval from the U.S. Food and Drug Administration (FDA) for Rybelsus tablets, which are semaglutide tablets for controlling type 2 diabetes in adults. Rybelsus controls the blood sugar level in type 2 diabetic patients by slowing down the digestion process. The slow rate of digestion reduces the amount of sugar produced by the liver and also helps the pancreas in producing more insulin when required.
